The global viral vector & plasmid DNA manufacturing market is expected to reach US$ US$ 2,247.7 million by 2027 from US$ 459.4 million in 2019. The market is estimated to grow with a CAGR of 22.1% from 2020 to 2027.
Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth.Additionally, growth in the global healthcare market is likely to have a positive impact on the market in coming years.
However the high cost associated with gene therapy is the major factor hindering the market growth.
Gene therapies offer an effective way for the treatment of genetic diseases, the acceptance and awareness of gene therapy continues to grow, especially in developed regions.The increase in awareness of gene therapies leads to market entry of new and established players for manufacturing various gene therapy technologies.
For instance, according to a study published by Alliance for Regenerative Medicine in 2018, the number of gene therapy-related clinical trials witnessed growth of an estimated 18.0% compared to the previous year across the world. This growth in the number of clinical trials indicates rise in awareness and massive investments.
Established companies, healthcare organizations, and research institutes are focusing on spreading awareness related to gene therapies as they offer a modern way of disease treatment.For instance, in 2018, Alliance for Regenerative Medicine announced the launch of a new foundation to promote comprehensive understanding and acceptance of gene therapies.
This newly formed organization will work to grow public awareness and benefits of certain gene therapy-based aspects such as cell therapy, tissue-engineering, gene editing, and organ regeneration.
The global viral vector & plasmid DNA manufacturing market is segmented by product and application.Based on product, the viral vector & plasmid DNA manufacturing marketis segmented into viral vectors and non-viral vectors.
The viral vectors segment held the larger share of the market in 2019 andis anticipated to register the higher CAGR during the forecast period.Based on application, the viral vector & plasmid DNA manufacturing markethas been segmented into cancer, inherited disorders, viral infections, and others.
The cancersegment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period.
National Institutes of Health, World Health Organization (WHO), European Medical Association, Centers for Disease Control and Prevention, Canada Foundation of Innovation, Contract Research Organizations, and Dubai Health Authority are some of the essential secondary sources included in the report.
Our reports have been used by over 10K customers, including:
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025. The global cell and gene therapy market is one of the fastest-growing segments...
Increasing incidence of chronic diseases, and government investments for cell-based research are set to drive the cell expansion market.’’ The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%. Growth in this market is largely driven by the increasing...
The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage...
The Allergy Immunotherapies market was valued at US$ million 1,819.18 in 2019 and is projected to reach US$ 4,185.89 million by 2027; it is expected to grow at a CAGR of 11.1% from 2020 to 2027. The growth of the allergy immunotherapies market is mainly attributed to factors such as growing prevalence of allergic disorders and technological...
The lyophilization services for biopharmaceuticals market was valued at US$ 702.06 million in 2019 and is projected to reach US$ 1,456.74 million by 2027; it is expected to grow at a CAGR of 9.7% during 2020-2027. The growth of the lyophilization services for biopharmaceuticals market is mainly attributed to factors such as rising demand...
200 pages •
By The Business Research Company
• Jul 2020
Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI, and MassBiologics. The global viral vectors & plasmid DNA market is expected to grow from...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.